Marker Therapeutics Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $5.6
- Today's High:
- $6.3
- Open Price:
- $6.3
- 52W Low:
- $0.6706
- 52W High:
- $9.68
- Prev. Close:
- $6.15
- Volume:
- 104142
Company Statistics
- Market Cap.:
- $47.92 million
- Book Value:
- 2.163
- Revenue TTM:
- $9.26 million
- Operating Margin TTM:
- -296.72%
- Gross Profit TTM:
- $-17125779
- Profit Margin:
- -142.92%
- Return on Assets TTM:
- -46.22%
- Return on Equity TTM:
- -115.8%
Company Profile
Marker Therapeutics Inc had its IPO on 2014-03-25 under the ticker symbol MRKR.
The company operates in the Healthcare sector and Biotechnology industry. Marker Therapeutics Inc has a staff strength of 67 employees.
Stock update
Shares of Marker Therapeutics Inc opened at $6.3 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $5.6 - $6.3, and closed at $5.77.
This is a -6.18% slip from the previous day's closing price.
A total volume of 104,142 shares were traded at the close of the day’s session.
In the last one week, shares of Marker Therapeutics Inc have increased by +6.07%.
Marker Therapeutics Inc's Key Ratios
Marker Therapeutics Inc has a market cap of $47.92 million, indicating a price to book ratio of 1.1336 and a price to sales ratio of 3.5926.
In the last 12-months Marker Therapeutics Inc’s revenue was $9.26 million with a gross profit of $-17125779 and an EBITDA of $-24194024. The EBITDA ratio measures Marker Therapeutics Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Marker Therapeutics Inc’s operating margin was -296.72% while its return on assets stood at -46.22% with a return of equity of -115.8%.
In Q2, Marker Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 3.5%.
Marker Therapeutics Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-3.18 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Marker Therapeutics Inc’s profitability.
Marker Therapeutics Inc stock is trading at a EV to sales ratio of 3.6408 and a EV to EBITDA ratio of -0.4721. Its price to sales ratio in the trailing 12-months stood at 3.5926.
Marker Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $21.96 million
- Total Liabilities
- $2.92 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $0
- Dividend Payout Ratio
- 0%
Marker Therapeutics Inc ended 2024 with $21.96 million in total assets and $0 in total liabilities. Its intangible assets were valued at $21.96 million while shareholder equity stood at $19.03 million.
Marker Therapeutics Inc ended 2024 with $0 in deferred long-term liabilities, $2.92 million in other current liabilities, 8799.00 in common stock, $-430500836.00 in retained earnings and $0 in goodwill. Its cash balance stood at $18.12 million and cash and short-term investments were $18.12 million. The company’s total short-term debt was $0 while long-term debt stood at $0.
Marker Therapeutics Inc’s total current assets stands at $21.96 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $1.75 million compared to accounts payable of $1.59 million and inventory worth $0.
In 2024, Marker Therapeutics Inc's operating cash flow was $0 while its capital expenditure stood at $0.
Comparatively, Marker Therapeutics Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $5.77
- 52-Week High
- $9.68
- 52-Week Low
- $0.6706
- Analyst Target Price
- $40
Marker Therapeutics Inc stock is currently trading at $5.77 per share. It touched a 52-week high of $9.68 and a 52-week low of $9.68. Analysts tracking the stock have a 12-month average target price of $40.
Its 50-day moving average was $5.73 and 200-day moving average was $3.08 The short ratio stood at 0.99 indicating a short percent outstanding of 0%.
Around 1231.1% of the company’s stock are held by insiders while 2382.5% are held by institutions.
Frequently Asked Questions About Marker Therapeutics Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens and kill tumor cells. The company’s MultiTAA-specific T cell therapies include autologous T cells for the treatment of lymphoma and selected solid tumors; allogeneic T cells for the treatment of acute myeloid leukemia (AML) and acute lymphoblastic leukemia; and off-the-shelf products in various indications. It is also developing MT-401, which is in Phase 2 clinical trial for the treatment of post-transplant AML; MT-401-OTS for the treatment of AML; and MT-601 for the treatment of pancreatic cancer and lymphoma. Marker Therapeutics was founded in 1999 and is headquartered in Houston, Texas.